Zhejiang Cheng Yi Pharmaceutical (603811.SH): Injection of choline sodium phosphate passes the generic drug consistency evaluation.
Chengyi Pharmaceuticals (603811.SH) announced that it has recently received approval and issuance from the National Medical Products Administration...
Zhejiang Cheng Yi Pharmaceutical (603811.SH) announced that recently, the company has received the Approval Notice for Drug Supplementary Application issued by the National Medical Products Administration. The company's production of Sodium Choline Phosphoryl Injection has passed the evaluation of generic drug quality and efficacy consistency.
Sodium Choline Phosphoryl Injection is mainly used for conscious disorders after acute craniocerebral trauma and brain surgery. As of the disclosure date of the announcement, the company has accumulated approximately RMB 4.2843 million (unaudited) in research and development investment for the consistency evaluation of this drug.
Related Articles
TENFU (06868) spent HK$5420 to repurchase 2000 shares on December 9th.
Shanghai Pharmaceuticals Holding (02607) will distribute an interim dividend of HK$1.3215 per 10 shares on February 6, 2026.
MGM China (02282) spent HK$870,200 on December 9 to repurchase 52,500 shares.
TENFU (06868) spent HK$5420 to repurchase 2000 shares on December 9th.
Shanghai Pharmaceuticals Holding (02607) will distribute an interim dividend of HK$1.3215 per 10 shares on February 6, 2026.
MGM China (02282) spent HK$870,200 on December 9 to repurchase 52,500 shares.
RECOMMEND
Baidu’s AI Ace Kunlunxin Prepares For Hong Kong IPO, Domestic Computing Power Faces Crucial Test
08/12/2025
Institutions Say Short-Term Volatility Does Not Alter Upward Trend Of Hong Kong Stocks, Hang Seng Index Still Expected To Challenge 30,000 Points Next Year
08/12/2025
As The 2025 Central Economic Work Conference Approaches, What New Expectations Lie Ahead For Next Year’s Economic Agenda? Institutions Forecast Five Key Highlights
08/12/2025
